Glenmark Pharmaceuticals Beheer
Beheer criteriumcontroles 1/4
De CEO Glenmark Pharmaceuticals is Glenn Saldanha, benoemd in Jan2001, heeft een ambtstermijn van 23.83 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 168.61M, bestaande uit 80% salaris en 20% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.35% van de aandelen van het bedrijf, ter waarde ₹ 1.46B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 6.5 jaar.
Belangrijke informatie
Glenn Saldanha
Algemeen directeur
₹168.6m
Totale compensatie
| Percentage CEO-salaris | 80.0% |
| Dienstverband CEO | 23.8yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 1.5yrs |
| Gemiddelde ambtstermijn bestuur | 6.5yrs |
Recente managementupdates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -₹10b |
| Jun 30 2024 | n/a | n/a | -₹16b |
| Mar 31 2024 | ₹169m | ₹135m | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | -₹2b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Compensatie versus markt: De totale vergoeding ($USD 2.00M ) Glenn } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 776.72K ).
Compensatie versus inkomsten: De vergoeding van Glenn is gestegen terwijl het bedrijf verliesgevend is.
CEO
Glenn Saldanha (54 yo)
23.8yrs
Tenure
₹168,610,000
Compensatie
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 23.8yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | no data | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | less than a year | ₹102.12m | geen gegevens | |
| Company Secretary & Compliance Officer | 7.8yrs | ₹5.53m | geen gegevens | |
| President and Chief Human Resources Officer | 2.8yrs | geen gegevens | geen gegevens | |
| President & Head of Global Pharmaceutical Development | 2.2yrs | geen gegevens | geen gegevens | |
| President & Chief Quality Officer | 1.2yrs | geen gegevens | geen gegevens | |
| President & Global Head of Formulation Operations | 1.2yrs | geen gegevens | geen gegevens | |
| President & Business Head of India Formulations | 1.3yrs | geen gegevens | geen gegevens | |
| President and Business Head of Europe & Emerging Markets | 1.8yrs | geen gegevens | geen gegevens | |
| President & Business Head of North America | less than a year | geen gegevens | geen gegevens | |
| Investor Relations Officer | no data | geen gegevens | geen gegevens |
1.5yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GLENMARK wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 26.1yrs | ₹168.61m | 0.35% ₹ 1.5b | |
| Executive Director of Corporate Services & Executive Director | 25.1yrs | ₹60.84m | 0.27% ₹ 1.1b | |
| Executive Director | 6.5yrs | ₹102.12m | geen gegevens | |
| President | less than a year | geen gegevens | geen gegevens | |
| Non Executive Director | 19.3yrs | ₹600.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.5yrs | ₹1.90m | 0.039% ₹ 160.1m | |
| Independent Non-Executive Director | 1.8yrs | ₹1.20m | geen gegevens | |
| Independent Non-Executive Director | 4.3yrs | ₹1.10m | geen gegevens | |
| Independent Non-Executive Director | 5.6yrs | ₹1.40m | geen gegevens |
6.5yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLENMARK wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).